Skip to main content
. 2016 Dec 22;56(9):1045–1055. doi: 10.1007/s40262-016-0492-2

Fig. 3.

Fig. 3

Individual t ½ estimates following a dose of 30 IU/kg rAHF-PFM and BAY 81-8973; a solid line indicates that a switch from rAHF-PFM to BAY 81-8973 leads to an expected increase in t ½ for this patient; a dashed line indicates a decrease in t ½ following a switch to BAY 81-8973. rAHF-PFM antihemophilic factor (recombinant) plasma/albumin-free method, t ½ half-life